Jazz Pharmaceuticals Inc. is raising about $58.5 million in a public offering to pay off a sizeable chunk of its outstanding debt ahead of an FDA decision on fibromyalgia drug JZP-6 (sodium oxybate), expected this fall. (BioWorld Today)